Wenseng “Wendy” Pan, J.D. & Ph.D.

Wenseng “Wendy” Pan, J.D. & Ph.D.

Wenseng “Wendy” Pan, J.D. & Ph.D. 文森

Dr. Wenseng “Wendy” Pan, leader of Goodwin’s Life Sciences practice in Asia, specializes in mergers and acquisitions, technology-based transactions, licensing and strategic partnerships as well as financing transactions (including both venture/private equity financings and IPOs), especially in the life sciences and technology industries and in cross-border settings.

She has advised private equity firms in leveraged buy-outs and has represented financial institutions, technology, media and telecoms (TMT), biopharmaceutical, manufacturing, publishing, electronics companies and retail chains in stock and/or cash acquisitions, mergers, tender offers and going-private transactions. Wendy has advised on mergers and acquisitions transactions with an aggregate value over US $10 billion. She also advises on company formation, corporate governance, private and public financings.

Dr. Pan has advised life sciences companies and technology companies in structuring and negotiating complex strategic transactions and other commercial arrangements. Her practice covers product and technology licensing, strategic partnerships and joint venture formations and research, product development and commercialization collaborations as well as mergers and acquisitions and private investments. She has deep experiences in representing licensors as well as licensees, involving a broad spectrum of technologies. As a former scientist and a registered U.S. patent attorney, she possesses a unique set of skills for counseling her clients on intellectual property-related issues.

Her deep legal experiences, coupled with her unparalleled understanding about the businesses and technologies and her pragmatic approach have made her a trusted advisor and go-to person in the U.S.-China life sciences communities. According to one of her clients, she “is an incredibly intelligent lawyer who finds solutions for her clients. She is very personable and responsive — very good to deal with. I recommend her highly. She is one of the few lawyers in China on whom I rely, she understands both the Chinese and U.S. markets.” She has been recognized as a “deal broker” by BioWorld Today.

Dr. Pan has been recognized by IFLR1000 as a leading lawyer for M&A. She was also a recipient of the Legal Services Award by China M&A Association. In addition, she is recognized in the 2016 edition of Who’s Who Legal: Life Sciences (Transactional) and ranked for excellence by the 2021 edition of Chambers Asia-Pacific.

She served for two terms on the Board of Directors of The BayHelix Group, a not-for-profit organization with the mission to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. She has led the BayHelix’s HK Biotech IPO Task force since its formation, which, in collaboration with other industry organizations, has made important contributions in shaping the industry.

Dr. Pan is fluent in Mandarin Chinese and English.




潘律师深厚的执业能力,加上她对企业业务和科技无可比拟的深刻理解和务实的态度,使她成为中美两地生命科学界信赖和首选的法律顾问。据她的一位客户说,潘律师“是一名非常聪明的律师,总能为客户找到解决方案。她和蔼可亲,反馈迅速——和她合作是乐事。我高度推荐她。她是少数我信赖的中国律师之一。她了解中美两地市场。”潘律师获BioWorld Today评为“擅于促成交易的人”。





Areas of Practice
Domaines D’Expertise





Dr. Pan’s experience in VC, PE, M&A, JV and licensing and strategic partnership in the life sciences industry includes advising:


Representative Matters



Mergers & Acquisitions; Joint Venture And PE Investments
  • R-Bridge Healthcare Investment Advisory, Ltd. on its $60 million non-recourse loan agreement with Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK). This transaction marks the first Chinese royalty-based financing.
  • OncoImmue in its sale to Merck for an upfront payment of $425 million in cash, plus sales-based milestones as well as regulatory milestones, as well as pre-sale restructuring and asset spin-off.
  • Allogene in forming a first-of-its kind joint venture with Overland Pharmaceuticals (backed by Hillhouse) to develop and commercialize allogeneic CAR-T to patients in Greater China and certain South East Asian countries and Overland’s $117 Million investment in the JV and Allogene’s licensing to the JV.
  • Regenacy Pharmaceuticals in forming a joint venture with 3E Capital in China, following 3E Capital’s equity investment in Regenacy. 
  • Impact Therapeutics in forming a joint venture with Junshi Biosciences in China to develop and commercialize a PARP inhibitor for the treatment of cancers in Greater China.
  • Xynomic in its merger with Bison Capital Acquisition Corp., a SPAC, in a Nasdaq IPO through a reverse take-over.*
  • Harbour BioMed in its financing by Advantech and Legend Capital and its subsequent acquisition of Harbour Antibodies BV.*
  • Lundbeck in its acquisition of Ovation Pharmaceuticals.*
  • LYFE Capital in its sale of shares in Hangzhou Kangji Medical to TPG Asia.*
  • Fresenius in its acquisition of calcitriol injectable asset from Xanodyne Pharmaceuticals.*
  • Ikaria in its sale of INOvent® to GE Healthcare Systems.*
  • Arch and Venrock in Hua Medicine’s $50m Series C financing.*
  • Mevion, a U.S. medical device company, in forming a joint venture with Hopu and Yuanming.*
  • BGI in its acquisition of Complete Genomics, Inc. through a tender offer.*
  • K&L Consulting in its merger with Fountain Medical.*
  • Tasly Pharmaceutical Holdings in forming a joint venture with Herbalife.*
  • Aland Nutrition Holding Limited in its acquisition of Zhejiang Catalent Jiangyuantang Biotechnology from Catalent Singapore.*
  • Catalent in establishing a joint venture with Shangpharma.*
  • Charles River in acquiring 75% ownership and forming a joint venture with Vital River.*
  • Stiefel (a GlaxoSmithKline company) in acquiring WBI-1001 from Welichem.*
  • China Kanghui Holdings in its US$816 million sale to Medtronic.*
  • LifeTech Scientific Corp in its global strategic partnership with Broncus Technology Inc.*
  • Ambrx in its sale to a Chinese consortium consisting of Fosun, WuxiApptec, Everbright and Hopu.*
  • Merck in forming a joint venture with Sun Pharmaceuticals to develop and commercialize innovative branded generic products in emerging marketing countries.
  • CBC Capital in forming a joint venture with LinkedIn to launch LinkedIn’s operations in China.
  • Cisco in establishing a US$ 200 million joint venture with China Electronics Software Information Service Co., Ltd
  • Warner Brothers in forming a joint venture with Tencent for distributing movie titles over the internet. 

*Denotes experience prior to joining Goodwin.

Life Sciences Strategic Partnership & Licensing Transactions
  • Zai Laboratory in its PIPE investment, licensing and strategic partnership transaction with Macrogenics involving four programs.
  • Neupharma in out-licensing the Greater China rights to its BRAF V600E inhibitor to Henlius.
  • BridGene Biosciences in its strategic research collaboration and licensing agreement with Takeda, using BridGene’s proprietary IMTAC™ to identify targets and small molecule drug candidates for Takeda to develop into therapeutic, with over $500 million potential milestone payments plus royalties. 
  • I-Mab in its collaboration and license transaction with Complix to use Complix’s Alphabody platform to discover and develop antibodies against two immuno-oncology intracellular targets.
  • Apollomics, Inc. in obtaining a worldwide (excluding Greater China) license from Edison Oncology, for the development and commercialization of EO1001, a protein tyrosine kinase inhibitor.
  • Beijing Tide Pharmaceuticals in its out licensing agreement with Graviton Therapeutics for an aggregate upfront and milestones of over $500 million.
  • Hinova in obtaining an exclusive license for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region.
  • HiFiBio Therapeutics in its collaboration and licensing transaction with Kite for AML.
  • I-Mab Biopharma in its licensing and strategic partnership transaction with AbbVie for its CD-47 program for up to $1.94bn, including $180m upfront payment.
  • RTW in a series of transactions with Cytokinetics, including Ji Xing, a biotech company backed by RTW, in obtaining an exclusive license from Cytokinetics, to develop and commercialize CK-274 in Greater China as well as equity investment in Cytokinetics and acquisition of royalty stream from Cytokinetics.
  • TransThera in granting an exclusive license to LG Chem under its rights for the development and commercialization of TransThera’s TT-01025 outside Greater China and Japan.
  • MyoKardia, Inc. (Nasdaq: MYOK) in granting LianBio an exclusive license and forming a strategic collaboration to develop and commercialize mavacamten in China and other Asian territories.
  • EpicenRx in its exclusive license agreement with Sciclone to co-develop and commercialize RRx-001, for the treatment of cancer in Greater China.
  • Laekna Therapeutics in obtaining from Novartis an exclusive global license on FAZ053.
  • Cloudbreak Bio-Pharmaceutical in its license agreement with China Grand Pharmaceutical related to CBT-001.
  • I-Mab in its strategic alliance with Kalbe Genexine Biologics, a joint venture of Kalbe Farma Tbk and Genexine, Inc. for the commercialization of two I-Mab discovered product candidates.
  • Flexion Therapeutics, Inc. in its exclusive license agreement with Hong Kong Tainuo Pharma Ltd. and Jiangsu Tainuo Pharmaceutical Co. Ltd. for the development and commercialization of Flexion’s product ZILRETTA® in Greater China.
  • a Chinese biotech company in obtaining global (ex-Japan) rights to a Phase II oncology program from a Japanese pharmaceutical company.
  • Shenzhen Salubris in its licensing and collaboration transaction with Japan Tobacco to obtain an exclusive license under JT’s intellectual property rights related to a hypoxia inducible factor in the Greater China;
  • A Chinese biotech company in obtaining from AstraZeneca an exclusive global license to AZD4547, a Fibroblast Growth Factor Receptors (FGFR) inhibitor for FGFR-driven cancers;
  • Ambrx in its licensing and collaboration transaction with Novocodex Biopharmaceuticals to jointly develop and commercialize Ambrx’s internally developed novel site-specific antibody-drug conjugates (ADCs);
  • Ambrx in entering a global research and development collaboration and license agreement with Beigene;*
  • Transcenta in obtaining exclusive licenses from Eli Lilly on a portfolio of novel biotherapeutics programs;*
  • Novocure in granting an exclusive license to Zai Lab;*
  • Everest Medicine in obtaining from Novartis an exclusive global license on FGF401.*
  • Laekna in obtaining from Novartis an exclusive global license on ASB183 and UPB795 and CFG920.*
  • Suzhou Kintor in obtaining from Pfizer an exclusive, worldwide license on PF-03446962.*
  • Merus N.V. in its strategic collaboration with Simcere on multiple bispecific antibodies.*
  • Xinogen in its license and collaboration agreement with Angiochem on ANG1005.*
  • Harbour BioMed Holdings in obtaining exclusive licenses to two antibody programs from HanAll.*
  • Xynomic in obtaining exclusive global licenses to abexinostat from Abbvie and two oncology programs from Boehringer Ingelheim.*
  • Armetheon in its licensing and collaboration agreement with Lee’s Pharmaceuticals on Tecarfrin.*
  • The Medicines Company in its licensing and strategic partnership agreement with SynBio Pharmaceuticals Inc. for IONSYS®.*
  • GlaxoSmithKline in connection with its research collaboration and license agreement with PeptiDream.*
  • GlaxoSmithKline in connection with the amendment of its Research Collaboration, License and Option Agreement with Isis Pharmaceuticals.*
  • Takeda in connection with its licensing and development and commercialization collaboration with Intra-Cellular Therapies in order to develop selective phosphodiesterase type 1 (PDE1) inhibitors.*
  • Lundbeck in connection with its collaboration and services agreement with Zenobia Therapeutics and Vernalis (R&D) Limited for developing drug candidates that inhibit LRRK2 activity.*
  • Lundbeck in its licensing and development and commercialization collaboration agreement with Kyowa Hakko Kirin regarding adenosine A2A antagonist products.*
  • GlaxoSmithKline in its antisense drug collaboration with Isis Pharmaceuticals for the development and commercialization of therapeutics for rare disease and infectious diseases.*
  • Valeant’s predecessor Biovail in its collaboration with Alexza Pharmaceuticals to develop and commercialize Staccato Loxapine and with Acadia Pharmaceuticals to develop and commercialize Pimavanserin.*
  • Takeda in its development and commercialization collaboration and technology transfer transaction with Alnylam relating to RNAi therapeutics.*
  • Shire in its development and commercialization collaboration with Alba Therapeutics for AT-1001.*
  • Adolor in its strategic collaboration with Pfizer for delta opioid agonists.*
  • Cardiokine in its development and commercialization collaboration with Biogen Idec for lixivaptan.* 

*Denotes experience prior to joining Goodwin.

Private and Public Financings
  • HiFiBiO in its $75m Series D financing co-led by Mirae Capital and B-Capital.
  • Apollomics in its $124m Series C financing led by PingAn Capital.
  • iNeuro in its Series A financing.
  • Hightide Therapeutics in its Series B+ financing.
  • AccurGen in its formation and Series Seed financing by Pharmaron.
  • ORI Capital in its Series A investment in AffyImmune.*
  • Alphamab in its pre-IPO restructuring and receiving over $100m investment from Advantech, PAG, China Reform, OrbiMed, Ally Bridge, etc.*
  • Xynomic Pharma in its pre-IPO financing from Northern Light and other investors.*
  • Perfect Ease Ventures in its convertible note investment in JHL in its going private/pre-IPO transaction.*
  • Junson Capital and other investors in obtaining an exclusive China right to certain diagnostic lab services from a US diagnostic lab and related Series A equity investment in Salvoe.*
  • Tasly in obtaining an exclusive China right to certain diagnostic lab services from CardioDx.*
  • VMS in its investment in Profusa, a US healthcare IT company.*
  • Arch and Venrock in Hua Medicine’s $50m Series C financing by Harvest Capital and other investors.*
  • Ascletis Bioscience Co Ltd. in connection with  investment by Goldman Sachs.*
  • Ascletis Bioscience Co Ltd. in connection with investments by investors lead by CBridge Capital.*
  • Elpiscience in its Series A financing by Lily Asia Ventures.*
  • Angex in its Series A financing by Lily Asia Ventures.*
  • Asieris in its Series B financing by Phoenix Capital.*
  • Hightide Bio in its Series A financing.*
  • GP Capital, a Shanghai based Chinese VC fund, in leading the Series C investment in MicuRx.*
  • OrbiMed in its Series A investment in CBT Bio, a US biotech company.*
  • GenEros Bio in its bridge financing and license from National University of Singapore.*
  • ZD Medical in its strategic investment in Varocto Inc.*
  • Asieris Biosciences in its bridge loan and Series A financing by Taifu Capital.*
  • Adagene Inc. in its Series A financing from Fidelity Biosciences, Fidelity Asia Growth, and WuXi Venture.*
  • Baker/Tisch Investments LLC in connection with its investments in GeneWorks and 7TM.*
  • Apollomics’ pending Hong Kong IPO.
  • Ambrx’s $126m NYSE IPO
  • Xynomic’s Nasdaq IPO through deSPAC.*
  • Alphamab’s $350 million HK IPO.*
  • Haohai Healthcare’s $305 million HK IPO.*
  • A life sciences company specialized in gene sequencing in its proposed HK IPO.*
  • The Goldman Sachs Group in a shelf take-down of €900 million floating rate notes and €350 million 6.5% notes.*
  • Goldman, Sachs & Co. as the underwriter of Providian Financial Corporation’s shelf take-down of $350 million convertible senior notes.*
  • Aon Capital Markets as the initial purchaser in a Rule 144A/ Regulation D offering of common stock and a Rule 144A/Regulation S offering of floating rate notes of Domestic in connection with an insurance securitization transaction.*
  • Hayes Lemmerz  International in a Rule 144A/Regulation S offering of senior unsecured notes in connection with its Chapter 11 reorganization.*

*Denotes experience prior to joining Goodwin.

  • R-Bridge Healthcare Investment Advisory,Ltd.与Paratek Pharmaceuticals,Inc.(纳斯达克股票代码:PRTK)签订6000万美元的无追索权贷款协议。这笔交易是中国以特许权使用费作为担保进行融资的首例。 
  • OncoImmue4.25亿美元现金预付款出售予默克公司(Merck),还包括基于销售的付款和监管里程碑付款,以及售前重组和资产剥离。
  • Allogene与高瓴旗下的瓴路药业(Overland Pharmaceuticals)成立具开创性的合资公司,专注于为大中华地区和部分东南亚国家的患者开发和商业化同种异体CAR-T癌症疗法。瓴路药业出资1.17亿美元,Allogene则提供许可。
  • 3E CapitalRegenacy Pharmaceuticals进行股权投资之后,两者在中国成立了一家合资企业。
  • 英派药业(Impact Therapeutics)与君实生物(Junshi Biosciences)在中国成立合资公司共同开发PARP抑制剂抗肿瘤药物。
  • XynomicSPAC壳公司贝森资本收购公司(Bison Capital Acquisition Corp.)合并,通过反向收购在纳斯达克进行上市。*
  • 铂医药(Harbour BioMed)通过尚珹資本(Advantech Capital)和君联资本(Legend Capital进行融资,以及随后收购Harbour Antibodies BV*
  • 丹麦制药公司Lundbeck购美国Ovation药公司。*
  • 济峰资本(LYFE Capital)向亚洲德太投资(TPG Asia)出售其杭州康基医疗器械的股份。*
  • 费森尤斯(Fresenius)收Xanodyne药公司的钙三醇注射资产。*
  • IkariaGE疗系统(GE Healthcare Systems)出售INOvent®产品。*
  • ArchVenrock对华领医药进行5000万美元C轮投资。*
  • 美国医疗设备公司Mevion与厚朴和元明資本成立一家中国合资公司。*
  • 华大基因研究院通过要约收购向Complete Genomics, Inc.进行收购。*
  • 上海鸿灵企业管理咨询公司与方恩医药进行合并。*
  • 天士力医药集团与康宝莱公司(Herbalife)成立合资公司。*
  • 兰得(香港)营养控股有限公司从新加坡Catalent药公司收购浙江康泰伦特江元堂生物科技公司。*
  • Catalent与尚华医药成立合资公司。*
  • 查尔斯河实验室(Charles River)收购维通利华(Vital River75%拥有权。*
  • StiefelGalxoSmithKyLine公司)从WeligHEM获取抗炎剂WBI-1001*
  • 中国康辉控股(China Kanghui Holdings)以8.16亿美元出售予美敦力(Medtronic)。*
  • 先健科技公司与Broncus术公司建立全球战略性合作伙伴关系。*
  • Ambrx出售予由复星、药明康德、光大和厚朴组成的中国财团。*
  • 默克公司与太阳制药(Sun Pharmaceuticals)成立合资企业,在新兴市场国家开发和商业化创新品牌仿制药。*
  • 宽带资本(CBC Capital)与领英(LinkedIn)成立合资公司,开展领英在中国的业务。*
  • 思科(Cisco)与hina Electronics Software Information Service Co., Ltd.成立价2亿美元的合资公司。*
  • 华纳兄弟(Warner Brothers)与腾讯(Tencent)成立了一家合资公司,通过互联网发行电影。*
  • 再鼎医药与MacroGenics之间上市后私募投资、许可协议和战略性合作交易,当中涉及四种产品。
  • 润新生物将其BRAF V600E抑制剂的大中华区使用权授予复宏汉霖。
  • BridGene Biosciences与武田制药达成了战略研究合作和许可协议,利用BridGene专有的化学蛋白质组学平台IMTAC™ 以确定武田制药的目标和小分子药物候选物,予武田药品开发成治疗靶点,涉及超过5亿美元的潜在里程碑付款以及特许权使用费。 
  • I-Mab与Complix公司的合作和许可交易,使用Complix的Alphabody平台发现和开发针对两个免疫肿瘤细胞内靶点的抗体。
  • 冠科美博从Edison Oncology获得全球(不包括大中华区)许可,用于开发和商业化蛋白酪氨酸激酶抑制剂EO1001。
  • 北京泰德制药股份有限公司与Graviton Therapeutics达成海外授权合作协议,首付款及里程碑付款总金额超过5亿美元。 
  • Hinova获得了AMC303在大中华区肿瘤领域的开发、生产和商业化的独家许可权。
  • HiFiBio TherapeuticsKite的合作和授权交易。
  • 天境生物(I-Mab Biopharma)与艾伯維(AbbVie)就其CD-47项目进行了授权和战略合作交易,交易金额高达19.4亿美元,其中包括1.8亿美元的预付款。
  • RTWCytokinetics进行了一系列交易,包括协助RTW旗下的箕星药业从Cytokinetics获得在大中华区开发和商业化CK-274的独家许可权、对Cytokinetics进行股权投资以及从Cytokinetics购其特许权使用费收入。
  • TransThera授予LG ChemTT01025在大中华区和日本以外的地区开发和商业化的独家权利。
  • MyoKardia纳斯达克股票代码:MYOK)授予联拓生物(LianBio)独家许可权,并达成战略合作,在中国和其他亚洲地区开发和商业化mavacamten
  • EpicenRxSciclone签订独家许可协议,共同合作开发及商业化RRx-001并将其用于各种癌症的治疗。
  • Laekna Therapeutics诺华获得FAZ053的独家全球许可权。
  • Cloudbreak Bio Pharmaceutical远大医药就CBT-001签订的许可协议。
  • 天境生物与Kalbe-Genexine BiologicsKalbe-Farma TbkGenexine的合资企业)结成战略联盟,以实现两种I-Mab产品候选物的商业化。
  • Flexion Therapeutics, Inc与香港泰诺制药有限公司和江苏泰诺制药有限公司达成独家许可协议,以在大中华地区开发和商业化Flexion ZILRETTA®产品。
  • 一家中国生物技术公司从一家日本制药公司获得肿瘤项目第二阶段的全球(日本除外)许可权。
  • 深圳信立泰药业与日本烟草公司达成许可和合作协议,获得了日本烟草公司在大中华区与缺氧诱导因子相关的知识产权的独家许可权。
  • 一家中国生物技术公司从阿斯利康获得AZD4547的独家全球许可证,AZD4547是一种用于FGFR驱动的癌症的成纤维细胞生长因子受体(FGFR)抑制剂。
  • AmbrxNovocodex Biopharmaceuticals达成授权和合作协议,共同开发和商业化Ambrx内部开发的新型位点特异性抗体药物缀合物(ADC)。
  • Ambrx与百濟神州签订了全球研发合作和许可协议。*
  • Transcenta从礼来公司获得了一系列新型生物治疗项目的独家许可权。*
  • Novocure授予再鼎医药(Zai Lab)独家许可权。*
  • Everest Medicine公司从诺华(Novartis获得FGF401的独家全球许可权。*
  • Laekna诺华获得ASB183UPB795CFG920的独家全球许可权。*
  • 苏州开拓从辉瑞(Pfizer获得PF-03446962的独家全球许可权。*
  • Merus N.V.Simcere就多种双功能抗体进行战略合作。*
  • XinogenAngiochemAng1005签署许可和合作协议。*
  • Harbour Biomed HoldingsHanall获得两个抗体项目的独家许可权。*
  • XynomicAbbvie获得Abexinostat的独家全球许可权,并从Boehringer Ingelheim获得两个肿瘤学项目。*
  • Armetheon与李氏大药厂就Tecarfrin签订了许可和合作协议*
  • 麦迪逊医药公司(The Medicines Company)与SynBio药公司就IONSYS®签署许可和战略合作协议。*
  • 兰素史克公司(GlaxoSmithKline)与PeptiDream的研究合作和许可协议。*
  • 兰素史克公司(GlaxoSmithKline)修改其与ISIS药公司的研究合作、许可和期权协议。*
  • 武田制药与细胞内疗法的许可、开发和商品化合作,以开发选择性磷酸二酯酶1型(PDE1)抑制剂。*
  • LundbeckZenobia TherapeuticsVernalisR&DLimited签订合作和服务协议,开发抑制LRRK2活性的候选药物。*
  • LundbeckKyowa Hakko Kirin就腺苷A2A拮抗剂产品签订了许可、开发和商品化合作协议。*
  • 兰素史克公司与ISIS药公司合作开发和商品化罕见疾病和传染病治疗药物。*
  • Valeant(前称Biovail)与阿莱克萨制药(Alexza Pharmaceuticals)合作,开发和商品化Staccato Loxapine,与Acadia Pharmaceuticals合作开发和商品化Pimavanserin*
  • 武田制药与AlnylamRNAI疗进行开发和商品化合作和进行技术转让交易。*
  • 尔公司(Shire)与Alba Therapeutics合作开发和商品化AT-1001*
  • Adolor辉瑞就鸦片Delta动剂进行战略合作。*
  • CardiokineBiogen-Idec合作开发和商品化Lixivaptan*
  • HiFiBiO完成7500万美元D轮融资,由Mirae Capital和B Capital领投。
  • Apollomics进行1.24亿美元C轮融资,由平安资本领投。
  • iNeuroA轮融资。
  • 君圣泰(Hightide Therapeutics)的B+轮融资。
  • 安可济(AccuraGen)的成立以及Pharmaron对其进行的种子融资。
  • ORI CapitalAffyImmune进行的A轮投资。*
  • Alphamab进行IPO前重组,并从尚珹資本、PAG、中国国新(China-Reform)、OrbiMed汇桥资本(Ally Bridge)等获得了超过1亿美元的融资。*
  • 诺药业从北极光创投(Northern Light)和其他投资者获得上市前融资。*
  • Perfect Ease VenturesJHL私有化/上市前交易中投资其可转债。*
  • 佳辰资本(Junson Capital)和其他投资者从一家美国诊断实验室获得某些诊断实验室服务的中国独家权利,以及对Salvoe进行A轮融资。*
  • 天士力(Tasly)从CardioDx获得部分诊断实验室服务的中国独家权利。*
  • VMS对美国医疗IT公司Profusa进行投资。*
  • ArchVenrock参与嘉实资本和其他投资者为华领医药(Hua Medicine)提供的5000万美元C轮融资*
  • Ascletis Bioscience Co.Ltd.有关高盛对其进行的投资。*
  • Ascletis Bioscience Co.Ltd.有关康桥资本(CBridge Capital)作为领投对其进行的融资。*
  • Elpiscience有关礼来亚洲基金(Lily Asia Ventures对其进行的A轮融资。*
  • Angex有关礼来亚洲基金对其进行的A轮融资。*
  • 亚虹医药(Asieris)有关凤凰资本(Phoenix Capital对其进行的B轮融资。*
  • Hightide BioA轮融资。*
  • 金浦投资(GP Capital),一家总部位于上海的中国风投基金,领投MichurxC轮投资。*
  • 奥博资本(OrbiMed对美国生物技术公司CBT Bio进行的A轮融资。*
  • GenEros Bio有关其过桥贷款和从新加坡国立大学取得的许可权。*
  • 执鼎医疗(ZD MedicalVarocto公司进行的战略投资。*
  • 亚虹医药的过桥贷款和泰富资本(Taifu Capital对其进行的A轮融资。*
  • 天演药业的A轮融资,投资者包括富达生物科技基金、富达亚洲成长基金和无锡创投集团。*
  • Baker/Tisch Investments LLCGeneWorks7TM进行的投资。*


Ms. Pan is ranked for excellence by the 2021 edition of Chambers Asia-Pacific.



In The News









Columbia University School of Law
(Harlan Fiske Stone Scholar)
PhD, Chemistry
Columbia University
(Pegram Award)
Fudan University
(First Class honors)


(获得Harlan Fiske Stone Scholar荣誉,担任《哥伦比亚亚洲法杂志》编辑)
哲学博士, Chemistry
(Pegram Award)



HK Registered Foreign Lawyer (New York)
New York
U.S. Patent and Trademark Office (USPTO)



香港注册外国律师 (美国纽约州)





Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique